Zalcitabine (Synonyms: 2',3'-Dideoxycytidine; ddC; Dideoxycytidine)

目錄號(hào): HY-17392 純度: 99.37%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Zalcitabine是有效的核苷類似物逆轉(zhuǎn)錄酶抑制劑，用于HIV感染相關(guān)研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Zalcitabine Chemical Structure

CAS No. : 7481-89-2

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥352	In-stock
25 mg	￥320	In-stock
50 mg	￥450	In-stock
100 mg	￥660	In-stock
200 mg	￥980	In-stock
500 mg	￥1663	In-stock
1 g		詢價(jià)
5 g		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Zalcitabine:

Zalcitabine (Standard) 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 8 篇科研文獻(xiàn)

•Signal Transduct Target Ther. 2023 Feb 24;8(1):79. [Abstract]
•Nat Commun. 2024 Aug 6;15(1):6685. [Abstract]
•Clin Cancer Res. 2022 Nov 30;CCR-22-1591. [Abstract]
•Int J Antimicrob Agents. 2019 Dec;54(6):814-819. [Abstract]
•Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2207280119. [Abstract]
•J Cell Biol. 2023 Oct 2;222(10):e202302037. [Abstract]
•Int Immunopharmacol. 2024 Nov 2;143(Pt 3):113546. [Abstract]
•Int J Mol Sci. 2023 May 11, 24(10), 8609.

Zalcitabine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

查看所有亞型

HIV HIV-1 HIV-2

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection.

IC₅₀ & Target

Target: HIV

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CEM-SS	CC₅₀	> 10 μM Compound: DDC	Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%. Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.	[PMID: 9240351]
CEM-SS	CC₅₀	16 μM Compound: ddC	Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
CEM-SS	CC₅₀	34 μM Compound: 2, ddC	Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50% Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%	[PMID: 10821705]
CEM-SS	CC₅₀	46 μM Compound: ddC	Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay	[PMID: 33711763]
CEM-SS	CC₅₀	46 μM Compound: ddC	Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay	[PMID: 33711763]
CEM-TK(-)	CC₅₀	7 μM Compound: ddC	Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
CEM-TK(-)	CC₅₀	8.3 μM Compound: ddC	Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay	[PMID: 33711763]
H9	EC₅₀	0.001 μM Compound: ddC	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.001 μM Compound: ddC	Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.079 μM Compound: dideoxycytidine	Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique	[PMID: 25587934]
HepG2	CC₅₀	< 10 μM Compound: ddC	Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method	[PMID: 25849312]
HepG2	CC₅₀	< 10 μM Compound: ddC	Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method	[PMID: 25849312]
HepG2	IC₅₀	< 10 μM Compound: ddC	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	IC₅₀	< 10 μM Compound: ddC	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	IC₅₀	< 10 μM Compound: ddC	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HepG2	IC₅₀	< 10 μM Compound: ddC	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HepG2	EC₅₀	1.4 μM Compound: 2',3'-Dideoxycytidine (ddC)	Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro	10.1016/S0960-894X(97)00422-8
HepG2	IC₅₀	252 μM Compound: 2',3'-Dideoxycytidine (ddC)	Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro	10.1016/S0960-894X(97)00422-8
HepG2 2.2.15	CC₅₀	233 μM Compound: ddc	Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells	10.1016/S0960-894X(97)00001-2
HL-60	IC₅₀	100 μM Compound: DDC	Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay. Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.	[PMID: 1695683]
MT2	CC₅₀	4 μM Compound: ddC	Cytotoxicity against human MT2 cells after 5 days by MTT assay Cytotoxicity against human MT2 cells after 5 days by MTT assay	[PMID: 24900627]
MT4	CC₅₀	> 100 μM Compound: ddC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay	[PMID: 33711763]
MT4	CC₅₀	> 100 μM Compound: 2, ddC	Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50% Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%	[PMID: 10821705]
MT4	CC₅₀	> 20 μg/mL Compound: DDC	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27214512]
MT4	CC₅₀	> 20 μg/mL Compound: DDN, DDC	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1007/s00044-013-0567-7
MT4	CC₅₀	> 94 μM Compound: DDC	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	> 94.69 μM Compound: Zalcitabine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21824782]
MT4	CC₅₀	> 94.69 μM Compound: DDC	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22591854]
MT4	CC₅₀	> 94.69 μM Compound: DDC	Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	> 94.69 μM Compound: DDC	Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	> 94.7 μM Compound: DDC	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22405288]
MT4	CC₅₀	> 94.7 μM Compound: DDC	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	CC₅₀	> 95 μM Compound: ddC	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24119448]
MT4	CC₅₀	> 95 μM Compound: DDC	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	> 95 μM Compound: DDC	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	> 95 μM Compound: DDC	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23084898]
MT4	CC₅₀	> 95 μM Compound: DDC	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 22883027]
MT4	IC₅₀	0.04 μg/mL Compound: ddC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 21658957]
MT4	IC₅₀	0.043 μg/mL Compound: ddC	Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 21658957]
MT4	EC₅₀	0.1 μg/mL Compound: ddC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	0.1 μg/mL Compound: ddC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	IC₅₀	0.16 μg/mL Compound: DDN, DDC	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	0.16 μg/mL Compound: DDC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	IC₅₀	0.19 μg/mL Compound: DDN, DDC	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	0.19 μg/mL Compound: DDC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	0.236 μM Compound: DDC	AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA). AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).	[PMID: 1695683]
MT4	EC₅₀	0.24 μM Compound: DDC	AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay	[PMID: 1695683]
MT4	EC₅₀	0.4 μM Compound: ddC	Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
MT4	EC₅₀	0.4 μM Compound: ddC	Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
MT4	EC₅₀	0.46 μM Compound: DDC	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.57 μM Compound: DDC	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.75 μM Compound: DDC	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.88 μM Compound: DDC	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	1 μM Compound: DDC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	EC₅₀	1 μM Compound: DDC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	1.04 μM Compound: DDC	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	1.28 μM Compound: DDC	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	1.3 μM Compound: DDC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	EC₅₀	1.3 μM Compound: DDC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	1.37 μM Compound: DDC; dideoxycytidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	1.39 μM Compound: DDC	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	1.4 μM Compound: ddC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay	[PMID: 24119448]
MT4	EC₅₀	1.468 μM Compound: Zalcitabine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	1.56 μM Compound: Zalcitabine	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	1.61 μM Compound: DDC	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	1.67 μM Compound: DDC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	1.7 μM Compound: DDC	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	1.7 μM Compound: DDC	Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	CC₅₀	10.66 μg/mL Compound: ddC	Toxicity against human MT4 cells by MTT assay Toxicity against human MT4 cells by MTT assay	[PMID: 21658957]
MT4	EC₅₀	1041.6 nM Compound: DDC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	CC₅₀	11 μg/mL Compound: ddC	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 12444692]
MT4	CC₅₀	130 μM Compound: ddC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay	[PMID: 33711763]
MT4	EC₅₀	1394.28 nM Compound: DDC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	CC₅₀	180 μM Compound: ddC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
MT4	EC₅₀	2.4 μM Compound: 2, ddC	Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay	[PMID: 10821705]
MT4	CC₅₀	30 μM Compound: D4C	Concentration required to reduce the number of viable uninfected MT-4 cells by 50%. Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.	[PMID: 1495007]
MT4	IC₅₀	313 μM Compound: DDC	Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay. Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.	[PMID: 1695683]
MT4	EC₅₀	33 μM Compound: ddC	Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method	[PMID: 11958995]
MT4	CC₅₀	40 μM Compound: ddCyd	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	CC₅₀	40 μM Compound: DDC	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	CC₅₀	48 μM Compound: ddC	Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method	[PMID: 11958995]
MT4	CC₅₀	75.2 μM Compound: ddC	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23419738]
MT4	CC₅₀	94.7 μM Compound: DDC	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
Vero	IC₅₀	0.02 μg/mL Compound: ddC	Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells	[PMID: 9548818]

體外研究
(In Vitro)

Zalcitabine 是一種二脫氧核苷類抗逆轉(zhuǎn)錄病毒劑，在未感染和 HIV 感染細(xì)胞內(nèi)均被磷酸化為活性代謝物 2',3'-二脫氧胞苷 5'-三磷酸 (ddCTP) 。ddCTP 抑制 HIV 的復(fù)制，通過抑制逆轉(zhuǎn)錄酶和終止前病毒 DNA 鏈的延長發(fā)揮作用；在 CHO/hOAT1 細(xì)胞中對(duì) [3H]-PAH 的細(xì)胞攝取表現(xiàn)出抑制作用，IC₅₀ 為 1.23 mM；增強(qiáng) hOAT1 活性可使其攝取增加三倍^[1]. ^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

211.22

Formula

C₉H₁₃N₃O₃

CAS 號(hào)

7481-89-2

性狀

固體

顏色

White to light yellow

中文名稱

扎西他賓；雙去氧胞嘧啶核酸

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 62.5 mg/mL (295.90 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

H₂O 中的溶解度 : ≥ 25 mg/mL (118.36 mM)

* "≥" means soluble, but saturation unknown.

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	4.7344 mL	23.6719 mL	47.3438 mL
5 mM	0.9469 mL	4.7344 mL	9.4688 mL
10 mM	0.4734 mL	2.3672 mL	4.7344 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.85 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (9.85 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (9.85 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

該產(chǎn)品水溶性佳，請(qǐng)具體參考實(shí)測水 / PBS / Saline 中的溶解度數(shù)據(jù)。

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測溶解度，如有需要，請(qǐng)與 MCE 中國技術(shù)支持聯(lián)系。

純度 & 產(chǎn)品資料

純度: 99.81%

選擇批次：

Data Sheet (636 KB) SDS (418 KB)

COA (289 KB) HNMR (257 KB) RP-HPLC (231 KB) MS (193 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Adkins JC, et al. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.Drugs. 1997 Jun;53(6):1054-80 [Content Brief]

[2]. Jin MJ, et al. Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2. [Content Brief]

Zalcitabine 相關(guān)分類

Infection

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	4.7344 mL	23.6719 mL	47.3438 mL	118.3594 mL
	5 mM	0.9469 mL	4.7344 mL	9.4688 mL	23.6719 mL
	10 mM	0.4734 mL	2.3672 mL	4.7344 mL	11.8359 mL
	15 mM	0.3156 mL	1.5781 mL	3.1563 mL	7.8906 mL
	20 mM	0.2367 mL	1.1836 mL	2.3672 mL	5.9180 mL
	25 mM	0.1894 mL	0.9469 mL	1.8938 mL	4.7344 mL
	30 mM	0.1578 mL	0.7891 mL	1.5781 mL	3.9453 mL
	40 mM	0.1184 mL	0.5918 mL	1.1836 mL	2.9590 mL
	50 mM	0.0947 mL	0.4734 mL	0.9469 mL	2.3672 mL
	60 mM	0.0789 mL	0.3945 mL	0.7891 mL	1.9727 mL
	80 mM	0.0592 mL	0.2959 mL	0.5918 mL	1.4795 mL
	100 mM	0.0473 mL	0.2367 mL	0.4734 mL	1.1836 mL

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zalcitabine7481-89-22',3'-Dideoxycytidine ddC Dideoxycytidine扎西他賓雙去氧胞嘧啶核酸HIVReverse TranscriptaseHuman immunodeficiency virusInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Zalcitabine (Synonyms: 2',3'-Dideoxycytidine; ddC; Dideoxycytidine)

Customer Review

Other Forms of Zalcitabine:

MCE 顧客使用本產(chǎn)品發(fā)表的 8 篇科研文獻(xiàn)

Zalcitabine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Zalcitabine 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Zalcitabine (Synonyms: 2',3'-Dideoxycytidine; ddC; Dideoxycytidine)

Customer Review

Other Forms of Zalcitabine:

Zalcitabine 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 8 篇科研文獻(xiàn)

Zalcitabine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Zalcitabine 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Zalcitabine 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z